Drug intelligence / Profile preview

glimepiride + metformin + pioglitazone

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

A triple combination antidiabetic medication containing glimepiride, metformin, and pioglitazone. Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells. Metformin is a biguanide that decreases hepatic glucose production, increases insulin sensitivity, and reduces intestinal glucose absorption. Pioglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues. This combination is used to treat type 2 diabetes mellitus when single or dual therapy is inadequate.

Brand names: Glimewell PM 2TriexerZoryl MP FortePiomed MGAmaryl MP
Other names: glimepiride + metformin + pioglitazone

Targets

NADH:ubiquinone oxidoreductase subunit familySUR1 (Sulfonylurea receptor 1)

Beyond the preview

Go deeper on glimepiride + metformin + pioglitazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glimepiride + metformin + pioglitazone.

Explore the full profile